GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

10 competitors in Influenza

MRNAmRNA Flu vaccine

BNTXInfluenza and COVID-19 Combination A

Phase 3

SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)

Phase 3

NVSSurface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008

Phase 2

BNTXInvestigational COVID-19 Vaccine

Phase 2

View Full Landscape

Drug Information

Target Indication

Influenza

Clinical Trial

NCT01051661

Last updated: 2/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Daprodustat smallPhase 3

Anaemia

diphtheria, tetanus, pertussis & Hib vaccinePhase 3

Tetanus

Rosiglitazone (BRL49653C)Phase 3

Diabetes Mellitus, Type 2

GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)Phase 3

Herpes Zoster

Ropinirole prolonged releasePhase 3

Parkinson Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts